RNN - Rexahn Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue----
Cost of Revenue----
Gross Profit----
Operating Expenses
Research Development13,109.05810,715.29610,089.14912,148.226
Selling General and Administrative7,428.6156,639.4216,324.2366,115.21
Non Recurring----
Others----
Total Operating Expenses20,537.67317,354.71716,413.38518,263.436
Operating Income or Loss-20,537.673-17,354.717-16,413.385-18,263.436
Income from Continuing Operations
Total Other Income/Expenses Net6,169.143-7,939.7867,106.043,878.88
Earnings Before Interest and Taxes-20,537.673-17,354.717-16,413.385-18,263.436
Interest Expense----
Income Before Tax-14,368.53-25,294.503-9,307.345-14,384.556
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-14,368.53-25,294.503-9,307.345-14,384.556
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-14,368.53-25,294.503-9,307.345-14,384.556
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-14,368.53-25,294.503-9,307.345-14,384.556